Pei Liu
President, Beijing OriginPoly Bio-Tec Co., Ltd , ChinaTitle: Application of methylation gene detection in precision diagnosis of endometrial carcinoma
Abstract
Endometrial cancer (EC) is the most
common gynecological cancer in high-income countries (cities), and its
incidence rate is on the rise in the world. the growth of obesity and metabolic
diseases are the main potential causes of EC. Abnormal uterine bleeding (AUB),
especially in postmenopausal women, is a common symptom of endometrial cancer.
However, AUB symptoms are very common, and only 0.3% of cases are caused by
endometrial cancer. The diagnosis of EC is through sequential transvaginal
ultrasound scan (TVUS), followed by invasive outpatient hysteroscopy and
endometrial biopsy, which is very painful in postmenopausal women and high
failure rate. At present, there are no methods and guidelines for EC screening.
As we know, the exfoliated malignant
cells of EC flow through the cervix to the lower reproductive tract. About 20-50%
of EC cases can be detected by cervical Papanicolaou (Pap) test. A new
noninvasive method to detect the DNA mutation or methylation level in Pap test
is feasible and encouraging.
In this presentation, I will first
share the highly specific methylation genes found in EC tissues and cervical
exfoliated cells. Secondly, clinical research was carried out to screen the
optimal gene combination with high sensitivity and specificity through
standardized detection process. Third, we verified the clinical significance
and clinical application of cervical scraping cells in a
single hospital. Finally, we used the standard kit (CISENDO DNA
methylation detection kit) to detect methylation genes in cervical scraping
cells for endometrial cancer in a multi-center clinical study, which included
more than 10000 women from 16 hospitals.
We will also share how to use endometrial cancer methylation gene
detection to improve the accuracy of hysteroscopy and reduce the number of
repeated curettages in women of childbearing age (fertility protection). According
to the clinical data, we reconsidered the clinical application of methylation
gene detection in endometrial cancer screening and treatment follow-up.
Biography
Dr. Pei Liu has completed his PhD at from
the Biochemistry and molecular biology, Chinese Academy of Agricultural
Sciences, China. He is a clinical molecular biology expert in China and has
developed several class III diagnosis products. He is committed to the clinical translational
medicine of gynecological cancer (disease) detection and the development of
expert consensus and guidelines in China. He has
many publications and has been responsible for and participated in many major
clinical projects and national development projects in China.
Organization Location
1309 Coffeen Avenue, STE 1200, Sheridan, Wyoming 82801, USA
Mail us at
Program Enquiry
gynecology@scientexconferences.com
General Queries
contact@scientexconferences.com
Registration Enquiry
finance@scientexconferences.com
gynecology@scientexevents.com
Our Social Presence
Call us at
USA: : (+1) 323 723 3691